1 February 2021 in Clinical Cancer Research
Systemic immunotherapies such as immune checkpoint blockade targeted at PD(L)1 and CTLA4 have demonstrated their ability to provide durable tumor responses and long-term overall survival benefits for some patients in several solid tumor types. However, a majority of patients remain resistant to these treatments and a significant proportion of them develop severe autoimmune and inflammatory adverse events. Preclinical studies have demonstrated that intratumoral injections of immunostimulatory products (oncolytics, pattern recognition receptor agonists,…) that are able to trigger type I IFN release and enhance tumor antigen presentation on immune cells could generate a strong antitumor immunity and overcome the resistance to systemic immune checkpoint blockade therapies. The intratumoral immunotherapy strategies that are currently in clinical development offer a unique therapeutic and exploratory setting to better understand the immune contexture across tumor lesions of patients with metastatic cancer. Also these local therapeutic products could turn cold tumors into hot and improve the response rates to cancer immunotherapies while diminishing their systemic exposure and toxicities. Intratumoral immunotherapies could prime or boost the immunity against tumors and therefore radically change the combinatorial therapeutic strategies currently pursued for metastatic and local cancers to improve their long-term survival. We aimed to review and discuss the scientific rationale for intratumoral immunotherapy, the challenges raised by this strategy in terms of drug development within clinical trials and the current state-of-the-art regarding the clinical practice of this innovative approach.
5 August 2022 in Cancer Discovery
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale. Significance: In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli–specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221
8 January 2021 in Clinical Cancer Research
Human intratumoral immunotherapy (HIT-IT) is under rapid development, with promising preliminary results and high expectations for current phase III trials. While outcomes remain paramount for patients and the referring oncologists, the technical aspects of drug injection are critical to the interventional radiologist to ensure optimal and reproducible outcomes. The technical considerations for HIT-IT affect the safety, efficacy, and further development of this treatment option. Image-guided access to the tumor allows the therapeutic index of a treatment to be enhanced by increasing the intratumoral drug concentration while minimizing its systemic exposure and associated on-target off-tumor adverse events. Direct access to the tumor also enables the acquisition of cancer tissue for sequential sampling to better understand the pharmacodynamics of the injected immunotherapy and its efficacy through correlation of immune responses, pathologic responses, and imaging tumor response. The aim of this article is to share the technical insights of HIT-IT, with particular consideration for patient selection, lesion assessment, image guidance, and technical injection options. In addition, the organization of a standard patient workflow is discussed, so as to optimize HIT-IT outcome and the patient experience.
18 June 2022 in European Journal of Cancer
20 August 2025 in Research Square
Intravenous anti-CTLA4 with anti-PD1 provides durable tumor responses but generates high rates of severe immune-related adverse events (irAEs) in cancer patients1-3. As opposed to anti-PD1 antibodies, anti-CTLA4 efficacy and toxicity is dose dependent, which limits its use in many patients and restricts broader application, particularly in localized cancers. Therefore, administering lower doses of anti-CTLA4 but directly into tumors and at high local concentrations could enhance anti-tumor efficacy while minimizing systemic exposure and toxicity. Conversely, stronger activation of tumor infiltrating lymphocytes could increase systemic toxicity in case of cross-reactivity with healthy tissue antigens. To challenge those hypothesis we launched a randomized multicenter Phase 1b NIVIPIT trial (NCT02857569), where 61 patients untreated metastatic melanoma patients were randomly assigned 2:1 to receive intravenous nivolumab (1mg/kg) in combination with either intratumoral (IT) ipilimumab (0.3mg/kg) or intravenous (IV) ipilimumab (3mg/kg). The primary endpoint was met with a significantly lower incidence of grade ≥ 3 irAEs at 6 months in the IT arm vs the IV arm (22.6% vs 57.1%), equivalent to anti-PD1 monotherapy, thereby demonstrating the safety of this approach. The RECIST 1.1 best objective response rate was 65.7% for anti-CTLA4 injected tumor lesions, and 50% for the non-injected lesions demonstrating an increased efficacy upon intratumoral anti-CTLA4 therapy. Baseline tumor immune profiling revealed that, unexpectedly, protumoral activated Tregs and M2 macrophages, were alongside HLA-I & II mediated adaptive T- & B-cells anti-tumor immunity predicting durable clinical benefit regardless of the anti-CTLA4 administration route. Upon anti-CTLA4 + anti-PD1 immunotherapy, intratumoral activated Tregs decrease and tumor-secreted Granzymes increase was found only in patients with durable clinical benefit. Our results provide the rationale for developing intratumoral anti-CTLA4 immunotherapy strategies in oligo-metastatic and earlier-stage cancers to avoid toxicities and suggest that persisting intratumoral regulatory–effector immune interface with high Tregs and M2 macrophages is a pre-requisite for anti-CTLA- 4 + anti-PD1 efficacy. Trial registration: ClinicalTrials.gov Identifier, NCT 02857569